Biofrontera Inc. Research and Development Expense
Biofrontera Inc. (BFRI) reported Research and Development Expense of $448.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Biofrontera Inc. research and development expense for the quarter ending 2026-06-30 was $448.00K, a 48.51% decline year-over-year.
- Biofrontera Inc. research and development expense for the quarter ending 2026-03-31 was $900.00K, a 25.43% decline year-over-year.
- Biofrontera Inc. research and development expense for the quarter ending 2025-12-31 was $787.00K, a 0.51% increase year-over-year.
- Biofrontera Inc. research and development expense for the quarter ending 2025-09-30 was $854.00K, a 27.65% increase year-over-year.
- Biofrontera Inc. research and development expense for fiscal 2025 was $3.72M, a 78.03% increase from fiscal 2024.
- Biofrontera Inc. research and development expense for fiscal 2024 was $2.09M, a 2612.99% increase from fiscal 2023.
- Biofrontera Inc. research and development expense for fiscal 2023 was $77.00K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $448.00K 10-Q · filed 2026-08-13 | $1.35M 10-Q · filed 2026-08-13 | $2.13M derived: sum of 3 quarters · filed 2026-08-13 | $2.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $900.00K 10-Q · filed 2026-05-14 | $1.69M derived: sum of 2 quarters · filed 2026-05-14 | $2.54M derived: sum of 3 quarters · filed 2026-05-14 | $3.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.64M derived: sum of 2 quarters · filed 2026-03-19 | $2.51M derived: sum of 3 quarters · filed 2026-08-13 | $3.72M 10-K · filed 2026-03-19 |
| 2025-09-30 | $854.00K 10-Q · filed 2025-11-12 | $1.72M derived: sum of 2 quarters · filed 2026-08-13 | $2.93M 10-Q · filed 2025-11-12 | $3.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $870.00K 10-Q · filed 2026-08-13 | $2.08M 10-Q · filed 2026-08-13 | $2.86M derived: sum of 3 quarters · filed 2026-08-13 | $3.53M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.21M 10-Q · filed 2026-05-14 | $1.99M derived: sum of 2 quarters · filed 2026-05-14 | $2.66M derived: sum of 3 quarters · filed 2026-05-14 | $3.28M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $783.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.45M derived: sum of 2 quarters · filed 2026-03-19 | $2.07M derived: sum of 3 quarters · filed 2026-03-19 | $2.09M 10-K · filed 2026-03-19 |
| 2024-09-30 | $669.00K 10-Q · filed 2025-11-12 | $1.29M derived: sum of 2 quarters · filed 2025-11-12 | $1.31M 10-Q · filed 2025-11-12 | $1.34M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $621.00K 10-Q · filed 2025-08-13 | $637.00K 10-Q · filed 2025-08-13 | $671.00K derived: sum of 3 quarters · filed 2025-08-13 | $704.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $17.00K 10-Q · filed 2025-05-15 | $50.00K derived: sum of 2 quarters · filed 2025-05-15 | $83.00K derived: sum of 3 quarters · filed 2025-05-15 | $94.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $66.00K derived: sum of 2 quarters · filed 2025-03-20 | $77.00K derived: sum of 3 quarters · filed 2025-03-20 | $77.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $33.00K 10-Q · filed 2024-11-14 | $44.00K derived: sum of 2 quarters · filed 2024-11-14 | $44.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $11.00K 10-Q · filed 2024-08-14 | $11.00K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |